Hutchmed China Limited Adr (HCM)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Hutchmed China Limited Adr Stock (HCM) Company Profile

Hutchmed China Limited Adr

Healthcare (1051)

Nächster Verdiensttermin

Neueste SEC-Einreichungen

HCM's Discussions on Twitter

Compare HCM vs TAK, TEVA, HLN, ZTS, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
HCM Hutchmed China Limited Adr	13.50	2.35B	549.97M	458.86M	-89.06M	2.6236
TAK Takeda Pharmaceutical Co Adr	18.52	59.16B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	41.25	48.11B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.44	41.51B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	74.30	30.70B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	543.40	23.31B	3.17B	1.29B	1.01B	27.09

Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-09-08	Hochstufung	HSBC Securities	Hold → Buy
2026-09-03	Hochstufung	Daiwa Securities	Hold → Buy
2025-09-22	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2025-05-13	Herabstufung	HSBC Securities	Buy → Hold
2023-11-24	Hochstufung	Deutsche Bank	Hold → Buy
2022-05-04	Herabstufung	Deutsche Bank	Buy → Hold
2021-09-22	Herabstufung	Goldman	Buy → Neutral
2021-08-03	Eingeleitet	Jefferies	Buy
2020-10-02	Eingeleitet	Deutsche Bank	Buy
2020-03-13	Eingeleitet	Cantor Fitzgerald	Overweight
2020-02-20	Eingeleitet	Goldman	Buy
2019-11-19	Eingeleitet	CLSA	Buy
2019-10-23	Bestätigt	BofA/Merrill	Buy
2019-07-05	Eingeleitet	Macquarie	Outperform

Alle ansehen

Hutchmed China Limited Adr Aktie (HCM) Neueste Nachrichten

Finanzdaten der Hutchmed China Limited Adr-Aktie (HCM)

Hutchmed China Limited Adr (HCM)

Hutchmed China Limited Adr Stock (HCM) Company Profile

Compare HCM vs TAK, TEVA, HLN, ZTS, UTHR

Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades

Hutchmed China Limited Adr Aktie (HCM) Neueste Nachrichten

HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer - GlobeNewswire Inc.

HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors - GlobeNewswire Inc.

HCM Q2 2023 Earnings: EPS Beat Consensus by 149.86% as Shares Edge HigherAnnual Report - dars.gov.et

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026 - GlobeNewswire Inc.

symbol__ Stock Quote Price and Forecast - CNN

Stevanato Group S.p.A. (STVN) Stock Price & News - Syfe

Zai Lab LimitedADR Peer Comparison – Compare with Others - valueresearchonline.com

China's Hutchmed inks $1.3 B deal with GSK for KRAS-EGFR-antibody conjugate cancer therapy - BioSpectrum Asia

Trinity Delta Lighthouse: HUTCHMED - Vox Markets

HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy - Yahoo Finance

HUTCHMED (NASDAQ:HCM) Shares Gap UpWhat's Next? - MarketBeat

Hutchmed Partners with GSK to Develop First-in-Class Cancer Drug in Licensing Deal Worth Up to $1.295 Billion - finance.biggo.com

Summit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday - benzinga.com

GSK backs HUTCHMED (China) (HCM) cancer drug in deal topping $1 billion - Stock Titan

HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy - GlobeNewswire

Mesoblast LimitedADR Peer Comparison – Compare with Others - Value Research

HUTCHMED (NASDAQ:HCM) Sees Large Volume IncreaseHere's What Happened - MarketBeat

Jupiter Neurosciences, Inc. Warrants (JUNSW) Peer Comparison – Compare with Others - Value Research

HUTCHMED (NASDAQ:HCM) Shares Pass Above Fifty Day Moving AverageHere's Why - MarketBeat

HUTCHMED’s SANOVO Phase III Trial Demonstrates Significant PFS Advantage for ORPATHYS Plus TAGRISSO in First-Line EGFR-Mutated Lung Cancer - Kalkine Media

HUTCHMED (HCM) lung cancer combo tops China Phase III trial - Stock Titan

HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China - Barchart.com

HUTCHMED (China) LimitedADR Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com

China grants conditional OK to HUTCHMED (HCM) ATLED after 42.5% response - Stock Titan

HUTCHMED (China) LimitedADR Key Financial Ratios – Valuation, Profitability & More - Value Research

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Rating of "Hold" from Brokerages - MarketBeat

HUTCHMED (HCM) Financial Update: EPS Beats Its Estimate in the Latest Reading; After Results: Shares Move 0.40% Down in the Available RecordAnalyst Earnings Estimate - careplusvn.com

HUTCHMED (HCM) Financial Update: EPS Beats Its Estimate in the Latest Reading; After Results: Shares Move 0.40% Down in the Available RecordFinancial Data - dars.gov.et

HUTCHMED (HCM) Financial Update: EPS Beats Its Estimate in the Latest Reading; After Results: Shares Move 0.40% Down in the Available RecordNet Income Trends - dars.gov.et

HUTCHMED (HCM) Financial Update: EPS Beats Its Estimate in the Latest Reading; After Results: Shares Move 0.40% Down in the Available RecordSegment Revenue Breakdown - dars.gov.et

HUTCHMED (NASDAQ:HCM) Shares Gap DownHere's Why - MarketBeat

HUTCHMED (NASDAQ:HCM) Sees Strong Trading VolumeShould You Buy? - MarketBeat

AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely Success - TradingView

HUTCHMED (HCM) flags director’s ex-role at firm in NIS3.1M insolvency case - Stock Titan

HUTCHMED (HCM) Latest Results Brief: The Bottom-Line Figure Beats Its Comparison for the Current Session; Trading-Day Reaction: Shares Close 0.64% Higher for the Current SessionEarnings Deceleration Risk - careplusvn.com

HUTCHMED (HCM) Latest Results Brief: The Bottom-Line Figure Beats Its Comparison for the Current Session; Trading-Day Reaction: Shares Close 0.64% Higher for the Current SessionProfit Margin Analysis - dars.gov.et

HUTCHMED (HCM) Latest Results Brief: The Bottom-Line Figure Beats Its Comparison for the Current Session; Trading-Day Reaction: Shares Close 0.64% Higher for the Current SessionEarnings Season Outlook - dars.gov.et

HUTCHMED (HCM) Latest Results Brief: The Bottom-Line Figure Beats Its Comparison for the Current Session; Trading-Day Reaction: Shares Close 0.64% Higher for the Current SessionEarnings Cycle Outlook - dars.gov.et

HUTCHMED (HCM) Latest Results Brief: The Bottom-Line Figure Beats Its Comparison for the Current Session; Trading-Day Reaction: Shares Close 0.64% Higher for the Current SessionNet Income Trends - dars.gov.et

HUTCHMED (HCM) lung cancer combo extends survival after TAGRISSO - Stock Titan

ETFs Investing in HUTCHMED (China) Limited Sponsored ADR Stocks - TradingView

HUTCHMED (HCM) Dips 0.98% to $12.13 — Key Support at $11.52 in FocusDelta Hedging - vinanet.vn

HUTCHMED (HCM) Dips 0.98% to $12.13 — Key Support at $11.52 in FocusStrangle Setup - careplusvn.com

HUTCHMED (HCM) Dips 0.98% to $12.13 — Key Support at $11.52 in FocusMomentum Breakout Ideas - dars.gov.et

HUTCHMED (HCM) Dips 0.98% to $12.13 — Key Support at $11.52 in FocusVolatility Skew - dars.gov.et

Hutchmed (HCM) Holds Near $12.47 as Biotech Sector Watches Support LevelFactor Rotation - careplusvn.com

HUTCHMED (NASDAQ:HCM) Share Price Crosses Above 50 Day Moving AverageHere's Why - marketbeat.com

REGHutchmed China LtdHUTCHMED Reports 2026 Interim Results - TradingView

HCM Q2 2023 Earnings: Strong EPS Beat Driven by Improved ProfitabilityEarnings Manipulation Risk - careplusvn.com

HCM Q2 2023 Earnings: Strong EPS Beat Driven by Improved ProfitabilityCash Flow Report - dars.gov.et

Finanzdaten der Hutchmed China Limited Adr-Aktie (HCM)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie HCM